Known targets — ChEMBL curated mechanism
PDE10APDE1APDE1BPDE1CPDE2APDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE6APDE6BPDE6CPDE6DPDE6GPDE6HPDE7APDE7BPDE8APDE8BPDE9ASLC29A1
The experimentally established mechanism targets of Dipyridamole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 known ✓ | Q99808 | 19/20 | 0.91 |
| ▸ | PDE2A known ✓ | O00408 | 1/20 | 0.91 |
| ▸ | PDE6D known ✓ | O43924 | 1/20 | 0.91 |
| ▸ | PDE8A known ✓ | O60658 | 1/20 | 0.91 |
| ▸ | PDE5A known ✓ | O76074 | 1/20 | 0.91 |
| ▸ | PDE6A known ✓ | P16499 | 1/20 | 0.91 |
| ▸ | PDE6G known ✓ | P18545 | 1/20 | 0.91 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.91 |
| ▸ | PDE6B known ✓ | P35913 | 1/20 | 0.91 |
| ▸ | PDE6C known ✓ | P51160 | 1/20 | 0.91 |
| ▸ | PDE1A known ✓ | P54750 | 1/20 | 0.91 |
| ▸ | PDE1B known ✓ | Q01064 | 1/20 | 0.91 |
| ▸ | PDE4B known ✓ | Q07343 | 1/20 | 0.91 |
| ▸ | PDE4C known ✓ | Q08493 | 1/20 | 0.91 |
| ▸ | PDE4D known ✓ | Q08499 | 1/20 | 0.91 |
| ▸ | PDE3B known ✓ | Q13370 | 1/20 | 0.91 |
| ▸ | PDE7A known ✓ | Q13946 | 1/20 | 0.91 |
| ▸ | PDE6H known ✓ | Q13956 | 1/20 | 0.91 |
| ▸ | PDE1C known ✓ | Q14123 | 1/20 | 0.91 |
| ▸ | PDE3A known ✓ | Q14432 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dipyridamole SCHEMBL17044166 | 0.95 | SLC29A1 (0.94) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL3980595 | 0.95 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL16119 | 0.95 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL30416820 | 0.95 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL29381078 | 0.95 | SLC29A1 (1.00) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL17017272 | 0.94 | SLC29A1 (0.86) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| SCHEMBL6915061 | 0.94 | SLC29A1 (0.86) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL7362290 | 0.94 | SLC29A1 (0.97) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL9743915 | 0.94 | SLC29A1 (0.97) | SLC29A1ADORA3KDM4EMEN1PDE2A | |
| Dipyridamole SCHEMBL28672572 | 0.94 | SLC29A1 (0.97) | SLC29A1ADORA3KDM4EMEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 185 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385548-B1 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH CARDIOVASCULAR AGENT(S) FOR THE TREATMENT OF VASCULAR CONDITIONS | SCHERING CORP (US) | 2007-05-23 | — | — | EP | claimed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-20240002440-A1 | AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER AND OTHER DISORDERS | JPMORGAN CHASE BANK, N.A. | 2024-01-04 | — | — | US | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2021-12-30 | — | — | US | disclosed |
| WO-2006124713-A2 | 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONES | MICROBIA, INC. (US) | 2006-11-23 | — | — | WO | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006086653-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1541175-A2 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | Schering Corporation (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1582168-A | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORP (US) | 2005-02-16 | — | — | CN | disclosed |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | SCHERING CORPORATION | 2003-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC29A1 2065/4885PDE2A 9/4885PDE6D 72/4885 |
| US-20210403508-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC29A1 2065/4885PDE2A 9/4885PDE6D 72/4885 |
| US-20030069221-A1 | Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions | CYP46A1, FABP2, SREBF1 | SLC29A1 512/4885PDE2A 752/4885PDE6D 2160/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | SLC29A1 2065/4885PDE2A 9/4885PDE6D 72/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | SLC29A1 2065/4885PDE2A 9/4885PDE6D 72/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | SLC29A1 2065/4885PDE2A 9/4885PDE6D 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.